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ABSTRACT
Using syngeneic BALB/c mouse breast cancer models, we show that the chromatin 
remodeling subunit bromodomain PHD finger transcription factor (BPTF) suppresses 
natural killer (NK) cell antitumor activity in the tumor microenvironment (TME). 
In culture, BPTF suppresses direct natural cytotoxicity receptor (NCR) mediated 
NK cell cytolytic activity to mouse and human cancer cell lines, demonstrating 
conserved functions. Blocking mouse NCR1 in vivo rescues BPTF KD tumor weights, 
demonstrating its importance for the control of tumor growth. We discovered that 
BPTF occupies heparanase (Hpse) regulatory elements, activating its expression. 
Increased heparanase activity results in reduced cell surface abundance of the NCR 
co-ligands: heparan sulfate proteoglycans (HSPGs). Using gain and loss of function 
approaches we show that elevated heparanase levels suppress NK cell cytolytic 
activity to tumor cells in culture. These results suggest that BPTF activates heparanase 
expression, which in turn reduces cell surface HSPGs and NCR co-ligands, inhibiting 
NK cell activity. Furthermore, gene expression data from human breast cancer tumors 
shows that elevated BPTF expression correlates with reduced antitumor immune cell 
signatures, supporting conserved roles for BPTF in suppressing antitumor immunity. 
Conditional BPTF depletion in established mouse breast tumors enhances antitumor 
immunity, suggesting that inhibiting BPTF could provide a novel immunotherapy.
INTRODUCTION
To escape antitumor immunity tumor cells suppress 
natural killer (NK) cell activity [1]. Toward this end, tumor 
cells alter ligand presentation to NK cell receptors by 
acquiring genetic and epigenetic changes to the genome 
[2]. Understanding how epigenetics affects these changes is 
important because epigenetic modifications are reversible 
and, therefore, could be corrected with therapeutics [3].
One class of NK cell activating receptors are the 
natural cytotoxicity receptors (NCRs) [4]. There are 3 NCRs 
in humans (NKp30, NKp44, and NKp46) and 1 in mice 
(NCR1). These receptors can control tumor growth in vivo, 
and promote cytolytic activity to cancer cells in vitro [5–8]. 
Both human and mouse NCRs recognize heparan sulfate 
(HS) chains on cell surface heparan sulfate proteoglycans 
(HSPG) [9]. These HS chains bind growth factors, cytokines 
and proteins to regulate a variety of biological processes [10]. 
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In mammals, HS are removed from HSPGs by heparanase 
to release bound factors and reorganize the extracellular 
matrix. In most normal cells HPSE expression is low, but it 
is commonly upregulated in many cancers to promote cell 
growth, motility, metastasis and inflammation [11].
One epigenetic regulator is the ATP-dependent 
chromatin remodeling complex, nucleosome remodeling 
factor (NURF). In mammals it is composed of 3 subunits: 
bromodomain PHD-finger containing transcription factor 
(BPTF), which is both essential and unique to NURF; 
the ISWI ATPase SNF2L; and the WD repeat protein 
pRBAP46/48 [12–14]. NURF slides nucleosomes in cis to 
alter accessibility of DNA for transcription factor binding, 
which ultimately regulates gene expression [12]. NURF 
is essential for embryonic development but is not cell 
essential [15, 16]. The BPTF gene is frequently amplified 
and overexpressed in a variety of cancers including 
breast, lung, and brain [17], though how NURF functions 
in cancer biology is just beginning to be understood. To 
better understand how epigenetic regulators, and NURF in 
particular, influence tumor biology, we pursued a loss of 
function approach using well established syngeneic breast 
cancer models.
RESULTS
NK cell-mediated antitumor immunity is 
enhanced to BPTF-depleted breast tumors
To investigate roles for NURF in cancer cell 
biology, we transduced the well-established 67NR 
and 66cl4 mouse breast cancer cell lines [18] with 
retroviruses expressing control (Ctrl-sh1 or Ctrl-sh2) or 
BPTF shRNAs (Bptf-sh1 or Bptf-sh2) (Figure 1A). BPTF 
knockdown (KD) was used to deplete NURF because 
it is unique and essential to the complex [13, 14]. In 
culture we observed equivalent doubling times, cellular 
morphology, and levels of apoptosis (Supplementary 
Figure 1A-1C). To discover novel roles for BPTF in 
tumor biology, we transplanted the 66cl4 or 67NR lines 
into the 4th mammary fat pad of syngeneic BALB/c mice. 
After 3-4 weeks, we observed reduced BPTF KD tumor 
weight (Figure 1B). Tumor weights were used instead 
of volume to measure growth because BPTF KD tumors 
grow flat, confounding volume-based comparisons to 
controls [19]. Microarray expression profiling of control 
and BPTF KD tumors discovered an enrichment of 
genes with gene ontology (GO) terms which included 
immune response descriptors (Supplementary Figure 
2A; Supplementary Data Set 1). In agreement with 
microarray data, KEGG analysis of a combined gene list 
from both tumor types identified an abundance of genes 
involved in the immune response (Figure 1C; for high 
resolution see Supplementary Figure 2B; Supplementary 
Data Set 1) [20]. To confirm the importance of the 
immune response for BPTF KD tumor growth, we 
repeated our tumor studies in an immune-deficient 
NOD/SCID, Ifrg2r-/- (NSG) background [21]. These 
experiments showed equivalent BPTF KD tumor weights 
to controls, demonstrating the immune system is required 
to reduce the growth of BPTF KD tumors (Figure 1D).
To identify immune cells that are important for 
reducing BPTF KD tumor growth, we repeated our tumor 
studies in mice depleted of NK cells, CD8+ T cells, or 
CD4+ T cells by monoclonal antibody (mAb) treatments. 
We observed improved growth of 67NR and 66cl4 BPTF 
KD tumors with NK cell depletion (anti-asialo-GM1 
mAb), but not with CD8+ or CD4+ T-cell depletion, 
indicating that NK cells are required for reduced BPTF KD 
tumor growth (Figure 1E) (Supplementary Figure 3A-3C).
We next examined the abundance and activation 
of NK cells in the BPTF KD tumor microenvironment 
(TME)[22]. This analysis showed a greater population 
of NK cells (CD3-, NCR1+) in 67NR tumors compared 
to 66cl4 tumors (Figure 2A). While present, the CD3-
, NCR1+ populations did not change with BPTF KD in 
66cl4 or 67NR TME (Figure 2B). However, we observed 
a greater percentage of NCR1+, CD69high cells in 67NR 
and 66cl4 BPTF KD tumors, demonstrating that a greater 
fraction of NK cells in BPTF KD tumors are activated as 
defined by CD69 expression (Figure 2C and 2D).
NK cell cytotoxic activity is enhanced to BPTF 
depleted cancer cells in vitro
Coculture of purified naive mouse NK cells with 
67NR and 66cl4 cells showed enhanced activation 
and cytolytic activity to BPTF KD targets (Figure 3A) 
(Supplementary Figure 4A-4D). To determine if BPTF 
KD cells are more sensitive to NK cell-mediated killing, 
we stimulated their cytolytic activities independent of 
ligand using PMA + ionomycin (P+I). P+I activated NK 
cells killed control and BPTF KD targets equivalently, 
indicating that BPTF KD targets are not more sensitive 
to lysis by NK cells (Supplementary Figure 4E). To 
determine if soluble factors enhance NK cell activity, 
we pre-incubated naive mouse NK cells with media 
from cultured control or BPTF KD 67NR or 66cl4 
tumor cells prior to their use in the cytolytic assay. From 
these experiments, we observed equivalent NK cell 
cytolytic activity toward BPTF KD targets with media 
preconditioned with either control or BPTF KD cells 
(Supplementary Figure 4F). These results in combination 
demonstrate that changes on the surface of BPTF KD 
tumor cells, as opposed to a soluble factor, improve NK 
cell activation and cytolytic activity.
We next determined if the enhanced NK cell cytolytic 
activity to BPTF KD targets is conserved between mice and 
humans. Toward this end, we cocultured the human NK-92 
cell line [23] with either mouse (67NR, 66cl4) or human 
(T47D, MDA-MB-436, SH-SY5Y) BPTF KD targets 
(Supplementary Figure 4G). From these experiments we 
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Figure 1: NK cells are required to reduce BPTF KD 67NR and 66cl4 tumor weight. (A) BPTF Western blot analysis from 
control (Ctrl-sh1, Ctrl-sh2) and BPTF KD (Bptf-sh1, Bptf-sh2) 67NR and 66cl4 total cell extracts. Cyclophilin B is used as a loading 
control. (B) 67NR and 66cl4 tumor weights harvested from BALB/c mice (n ≥ 11 biological replicates, * = ttest pvalue < 0.003). (C) 
Low resolution KEGG pathway analysis of 67NR and 66cl4 significantly deregulated genes highlighting clusters of genes with function 
in the immune system (For high resolution please refer to Supplementary Figure 2B). (D) 67NR and 66cl4 tumor weights harvested from 
NSG mice (n = 9 biological replicates). (E) 67NR and 66cl4 tumor weights harvested from undepleted, or CD8, CD4 or asialo-GM1 mAb 
depleted BALB/c mice (n = 6 biological replicates, * = ttest pvalue < 0.05). Some dots overlap.
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observed enhanced cytolytic activity to all BPTF KD cell 
lines, indicating that changes leading to enhanced cytolytic 
activity are conserved (Figure 3B and 3C).
BPTF regulates cell surface HSPG abundance 
and Hpse expression
We conducted microarray gene expression ana-
lyses of control and BPTF KD 67NR and 66cl4 tumors 
from NSG mice to identify candidate BPTF-regulated 
NK cell receptor ligands. Analysis of these data sets 
focused on activating receptor ligands because they 
are conserved between mice and humans [24]. This 
is not true of the inhibitory MHC ligands which are 
species restricted in activity [25], and not significantly 
BPTF regulated in 67NR or 66cl4 cells (Supplementary 
Figure 5A). Combined qRT-PCR and microarray 
experiments identified three BPTF regulated genes with 
functions in HS metabolism (Ndst1, Ndst3, Hpse) but did 
not identify any known activating NK cell receptor ligands 
(Figure 4A; Supplementary Figure 5B; Supplementary 
Data Set 1). HS and HSPGs are well characterized co-
ligands for the NCRs, which are required for efficient NK 
cell-mediated tumor cell killing [26, 27].
Because HS is a known co-ligand to all NCRs, it is 
plausible that the enhanced NK cell cytolytic activity to 
BPTF KD cells occurs through the NCRs. mAb blocking 
of NKp30, but not NKp46 or NKG2D, on NK-92 cells 
inhibited the enhanced cytolytic activity against BPTF 
KD 66cl4 targets (Figure 4B). NKp44 was not included in 
our blocking studies because NK-92 cells do not express 
NKp44 [28]. NKp30 is highly expressed and is a major 
NCR used by NK-92 cells for antitumor activity [28, 29]. 
Functions for NKp30 in promoting NK cell activity to 
BPTF KD cells is conserved as demonstrated by reduced 
NK-92 cytolytic activity toward BPTF KD T47D targets 
with NKp30 blocking (Figure 4C). Similar reductions 
in mouse NK cell cytolytic activity was observed after 
NCR1 mAb blocking, the only NCR expressed in mouse 
NK cells (Figure 4D) [30]. Also, the addition of the NCR 
competitive inhibitor heparin [9] erased the NK-92 and 
mouse NK cell cytolytic activity against 67NR and 66cl4 
BPTF KD targets (Supplementary Figure 5C and 5D).
We next used a recombinant NCR1-Ig fusion 
protein to measure the abundance of NCR1 ligands on the 
surface of BPTF KD 67NR and 66cl4 cells. From these 
experiments, we discovered enhanced binding of NCR1-Ig 
to BPTF KD cells (Figure 4E and 4F). We then measured 
NCR1 activation using a cell line with an Il-2 reporter 
regulated by an NCR1-ζ fusion receptor [31]. Coculture 
experiments show elevated Il-2 gene expression when 
in contact with BPTF KD 67NR and 66cl4 cells (Figure 
4G) (Supplementary Figure 5E), further suggesting that 
enhanced NK cell cytolytic activity results from increased 
NCR1 activity. We next used the NCR1 blocking mAb in 
tumor bearing mice and observed that BPTF KD tumor 
weights are rescued with NCR1 blocking (Figure 4H). As 
previously reported after NCR1 blocking mAb treatments 
NK cells are not depleted and cell surface NCR1 decreases 
(Supplementary Figure 5F and 5G)[32].
Figure 2: NK cells are more active in BPTF depleted 
tumor microenvironments. (A) Representative flow 
cytometry dot plots of live tumor infiltrating NK cells stained 
with CD3ε and NCR1. (B) Percentages of live CD3ε-, NCR1+ 
NK cells from A (n ≥ 6 biological replicates). (C) Representative 
flow cytometry dot plots of live tumor infiltrating NK cells stained 
with CD69 and NCR1. CD69high is defined by CD69 staining of 
live CD3ε- NCR1+ cells from the spleen. (D) Percentages of live 
NCR1+ cells that are CD69high (n = 6 biological replicates, * 
= ttest pvalue < 0.006). Quantitative data shown represent mean 
± stdev.
Oncotarget64348www.impactjournals.com/oncotarget
Our expression analysis identified Hpse,  the major 
regulator of cell surface HS abundance, as a BPTF-
regulated gene in both 67NR and 66cl4 BPTF KD tumors 
(Figure 4A)[33]. These results were confirmed in culture 
for the 67NR, 66cl4, T47D, SH-SY5Y, and MDA-MB-436 
cell lines (Figure 5A) (Supplementary Figure 5H). In 
addition, an analysis of BPTF and HPSE expression in 
human cancers from the TCGA data sets revealed a highly 
significant correlation between high BPTF expression and 
high HPSE expression in several cancer types including 
breast (see arrow) (Figure 5B). Consistent with Hpse 
gene expression, Western blotting discovered significant 
reductions in cell surface heparanase abundance with 
BPTF KD (Figure 5C). The importance of heparanase 
for enhanced NK cell activity to BPTF KD cells was 
investigated using bacterial heparinase treatments and 
heparanase KD cell lines. Pretreatment of tumor cells 
with bacterial heparinase suppressed the enhanced 
binding of NCR1-Ig to BPTF KD cells (Figure 5D) and 
reduced the enhanced cytolytic activity of NK cells to 
66cl4 BPTF KD targets (Supplementary Figure 5I). 
Similarly, we observed that heparanase KD in control 
66cl4 cells results in enhanced NK cell cytolytic activity, 
consistent with heparanase abundance regulating NK cell 
activity (Supplementary Figure 5J and 5K). To determine 
if decreased Hpse expression with BPTF KD correlates 
with changes in cell surface HSPGs, we measured HSPG 
abundance by Western blotting cell surface protein 
extractions using an antibody to HS. Three HSPGs from 
these experiments had reproducibly increased levels in 
BPTF KD cells: a ~150 kDa band, a ~55 kDa band and 
a ~45 kDa band (Figure 5E, see arrows). It is unlikely 
that expression of the HSPG core proteins are BPTF-
dependent because they were not BPTF-dependent 
from our microarray analyses (Supplementary Figure 
5L). Additionally, only the MMP2 HSPG sheddase was 
deregulated in 67NR, but not 66cl4, BPTF KD NSG 
tumors, suggesting that HSPG cell surface shedding is not 
BPTF-dependent (Supplementary Figure 5L). In addition, 
NURF occupies regulatory elements of Hpse because 
chromatin immunoprecipitation (ChIP) revealed BPTF 
occupancy broadly localized at the Hpse gene in 67NR and 
localized at the Hpse promoter in 66cl4 cells (Figure 5F) 
[34]. From these results, we propose a model where NURF 
activates Hpse in cancer cells, either directly or indirectly, 
elevating cell surface heparanase and reducing cell surface 
HSPGs. Because HSPGs are known co-ligands for NCRs, 
our model predicts that NURF suppresses NCR-mediated 
NK cytolytic activity by upregulating heparanase levels 
(Figure 5G).
BPTF depletion enhances the immune response 
to established tumors
To determine if BPTF suppression of the antitumor 
immune response could be conserved in human tumors, 
we monitored the immune cell composition from human 
breast tumor microarray data sets using the CIBERSORT 
algorithm [35]. From this analysis, we observed an 
enrichment of γδ T cells, resting CD4 T cells and B 
cells in tumors with high BPTF expression. Conversely, 
tumors expressing low levels of BPTF are enriched for 
active dendritic cells, macrophages, neutrophils, CD8+ 
T cells and Treg cells (Figure 6A). These results suggest 
that low BPTF levels correlate with increased abundance 
and activity of immune cells in human breast tumors. 
These results are supported by an independent analysis 
of the larger breast cancer provisional TCGA RNA-
Seq data set [36]. This analysis revealed an increase in 
the expression of CD8 T cell, NK cell, macrophage and 
Treg cell markers, and immune cell cytokines in breast 
tumors with low levels of BPTF expression(Figure 6B) 
(Supplementary Figure 6A). We observe increased NKp44 
(NCR3) expression but not NKp46 (NCR1) possibly 
because the elevated IL2 expression in BPTF low tumors 
could downregulate NKp46 [37].
Figure 3: NK cells have greater cytolytic activity to 
BPTF KD targets. (A-C) Percent target cell cytolytic activity 
by LDH assay. (A) NK cells from naive BALB/c mice were 
cocultured with targets at the indicated effector:target (E:T) 
ratios (n = 3 biological replicates, * = ttest pvalue < 0.05). (B) 
NK-92 cells were cocultured with targets at the indicated E:T 
ratios (n = 3 biological replicates, * = ttest pvalue < 0.05). (C) 
NK-92 cells were cocultured with human targets at a 10:1 E:T 
ratio (n ≥ 3, * = ttest pvalue < 0.05). Quantitative data shown 
represent mean ± stdev.
Oncotarget64349www.impactjournals.com/oncotarget
To further test this model, we injected established 
66cl4 and 4T1 tumors with replication-deficient adenovirus 
(rAd) expressing control or BPTF KD shRNA. 67NR 
tumors could not be used for these experiments because 
they undergo apoptosis after transduction by rAd in culture 
(data not shown). We had previously shown that BPTF 
KD 4T1 tumors upregulate antigen processing genes to 
improve the CD8+ T cell antitumor response [19]. Western 
blot analysis of 66cl4 and 4T1 treated tumors show that rAd 
treatments resulted in BPTF KD (Figure 6C). BPTF KD 
in established tumors significantly reduced tumor weights 
compared to controls (Figure 6D), and we occasionally 
observed complete 66cl4 tumor regression with BPTF 
KD (rAd BPTF shRNA = 3 of 17 treated tumors, rAd 
control shRNA = 0 of 16 treated tumors). To measure the 
effects of BPTF KD on the antitumor immune response, 
we monitored the activation of NK and CD8+ T cells in 
66cl4 and 4T1 tumors, respectively. Consistent with our 
previous studies, BPTF KD in established tumors resulted 
in a greater percentage of CD69high NCR1+ NK cells in 
the 66cl4 TME, or CD69high CD8+ T cells in the 4T1 TME 
(Figure 6E). Increased activation of NK and CD8+ T cells 
coincided with elevated IFNγ, suggesting a conversion to a 
Th1 TME (Figure 6F). As a control, transduction of NK-92 
cells and splenic mouse OT1 T cells in culture with rAd to 
achieve BPTF KD followed by coculture assays show that 
BPTF KD does not significantly alter NK or T cell cytolytic 
activity (Supplementary Figure 6B-6F). These results 
indicate that these effector cells are likely functional after 
BPTF KD rAd treatments.
DISCUSSION
Understanding how tumors escape the immune 
response is of great interest to tumor immunologists. 
Epigenetic escape mechanisms, most prominently DNA 
methylation and histone deacetylation, suppress tumor 
cell antigenicity to inhibit T cells, and ligand expression to 
Figure 4: NK cell cytolytic activity to BPTF KD cells requires NCRs. (A) Changes in NK receptor ligand expression measured 
by microarray in BPTF KD tumors harvested from NSG mice compared to controls. Hpse was measured independently by qRT-PCR 
because it was not on the microarray (* = ttest pvalue < 0.00002). (B-D) Percent target cell cytolytic activity by LDH assay. (B) NK-92 
cells pretreated with anti-NKp46, anti-NKp30 or anti-NKG2D mAb were cocultured on 66cl4 targets at a 10:1 E:T ratio (n = 3 biological 
replicates, * = ttest pvalue < 0.05). (C) NK-92 cells pretreated with anti-NKp30 were cocultured with T47D targets at a 10:1 E:T ration (n 
= 3 biological replicates, * = ttest pvalue < 0.05). (D) Mouse NK cells pretreated with anti-NCR1 blocking mAb (clone mNCR1.15) were 
cocultured with 66cl4 targets at a 5:1 E:T ratio (n = 3 biological replicates, * = ttest pvalue < 0.04). (* = significant to no mAb Ctrl-sh1, ** 
= significant to the respective no mAb hairpin). (E) Representative flow cytometry histograms of NCR1-Ig binding to 67NR and 66cl4. (F) 
Fold change of MFI from D (n = 3 biological replicates, * = ttest pvalue < 0.03). (G) qRT-PCR analysis of Il-2 expression in Ncr1-ζ, Il-2 
reporter BW cells incubated with control or BPTF KD cells for 48 hrs (n ≥ 3 biological replicates, * = ttest pvalue < 0.05). (H) 67NR and 
66cl4 tumor weights harvested from untreated or mNCR1.15 treated BALB/c mice (n ≥ 4 biological replicates, * = ttest pvalue < 0.05). All 
quantitative data shown represent mean ± stdev.
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Figure 5: BPTF regulates Hpse expression. (A) qRT-PCR analysis of Hpse expression from 67NR and 66cl4 cells (n = 3 biological 
replicates, * = ttest pvalue < 0.006). (B) Differential Hpse expression in BPTF high and BPTF low expression groups from TCGA datasets. 
The negative base 10 log of the p-value for each t-test is shown. Dashed line: significance cutoff pvalue = 0.05. Filled circles: positive 
correlation. Outlined circles: negative correlation. Breast cancer data set is shown with arrow. (C) Western blot analysis of cell surface 
HPSE from control and BPTF KD 67NR and 66cl4 cells. Cyclophilin B was used as a normalization control. (D) Representative flow 
cytometry histogram of NCR1-Ig binding to bacterial heparinase treated tumor cells. (E) Western blot analysis of cell surface HSPG 
using anti-HS primary mAb. Cyclophilin B was used as a normalization control. Arrows: reproducible changes in HSPG abundance with 
BPTF KD. ImageJ relative quantitation to controls are shown as numbers below blots. (F) BPTF ChIP at mouse Hpse in control and BPTF 
KD 67NR and 66cl4 cell lines (n = 3 biological replicates, * = ttest pvalue < 0.04). (G) A Model: In tumor cells NURF stimulates Hpse 
expression, and as a result cell surface heparanase abundance. Increased heparanase abundance reduces cell surface HSPGs and NCR 
HS co-ligand abundance, inhibiting NK-cell antitumor activity. When NURF is depleted, Hpse expression and heparanase is reduced. 
Reduced heparanase abundance increases cell surface HSPGs and NCR HS co-ligands, improving NK cell-mediated antitumor activity. All 
quantitative data shown represent mean ± stdev.
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Figure 6: BPTF is required for an immune suppressive tumor microenvironment. (A) Differential immune profiles identified 
using CIBERSORT between BPTF high and BPTF low expression groups from microarray expression profiles (* = ttest pvalue < 0.1). (B) 
Differential expression of immune cell markers in BPTF high and BPTF low expression groups from Zscore normalized expression data 
from breast cancer TCGA datasets (pvalues are shown in panel). (C) BPTF Western blot analysis of 66cl4 and 4T1 tumors injected with rAd 
expressing either control or BPTF KD shRNAs. Cyclophilin B was used as a loading control. ImageJ relative quantitation to controls are 
shown as numbers below blots. (D) Weights of 66cl4 and 4T1 tumors after treatment with rAd (n ≥ 6 biological replicates, * = ttest pvalue 
< 0.000003). (E) Flow cytometry analysis of 66cl4 tumor infiltrating NK cells and 4T1 tumor infiltrating CD8+ T cells. Active lymphocytes 
are quantified as percent CD69high of total infiltrating NK cells (NCR1+) or CD8+ T cells (CD8+) (n ≥ 4 biological replicates, * = ttest 
pvalue < 0.01). (F) IFNγ concentrations from 66cl4 and 4T1 tumor extracts measured by ELISA (n ≥ 6 biological replicates, * = ttest pvalue 
< 0.04). All quantitative data shown represent mean ± stdev.
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inhibit NK cells [38]. Because many epigenetic regulators 
are required for gene expression, chromatin remodeling is 
predicted to have similar functions in tumor cells. Using 
transplantable tumor models, we tested this prediction and 
discovered that BPTF, and by extension NURF, represses 
NK-mediated antitumor activity. We also observed pro-
tumor NK cell activities to 66cl4 tumors, which the use 
of a NCR1 blocking mAb suggest are NCR1 mediated. 
NCR1 expressing NK cells and immature lymphoid cells 
can control the immune response by direct killing of 
dendritic cells and T cells [39, 40], which could suppress 
an adaptive immune response to 66cl4 tumors, possibly 
explaining their pro-tumor activities. In total, these results 
support the idea that BPTF is a novel regulator of the NK 
cell-mediated antitumor immune response.
To identify BPTF-dependent NK receptor ligands, 
we used two complementary approaches. We first used 
the human NK-92 cell line to demonstrate that the BPTF-
regulated ligand(s) are conserved across species, and second 
used microarrays to discover that components of the HS 
synthesis and degradation pathways are BPTF-dependent 
in tumors. The most noteworthy BPTF-regulated factor 
discovered was the HS degrading enzyme heparanase, an 
enzyme which is highly conserved in both sequence and 
function between mouse and humans [41]. NURF could 
directly regulate Hpse expression because BPTF occupies 
its regulatory elements, but it is also equally possible that 
NURF regulates Hpse indirectly. Characterizing NURF-
regulated chromatin remodeling activities and mechanisms 
of NURF recruitment to these regulatory elements would be 
required to support a model where NURF directly regulates 
Hpse. Using similar approaches we discovered that NURF 
directly regulates chromatin structures surrounding CTCF 
binding sites to influence their regulatory activity [15]. One 
possibility is that NURF could be recruited to the Hpse 
promoter through its ability to bind the promoter associated 
histone modifications H3K4me3 and H4K16ac [42]. 
Alternatively, NURF could be recruited to Hpse regulatory 
elements through interactions with novel transcription 
factors [12].
HS and HSPGs are highly conserved, common co-
ligands to all NCRs, and they influence NK cell-mediated 
antitumor immunity in both humans and mice [5, 9, 
11]. Consistent with BPTF regulating the expression of 
NCR co-ligands, NKp30 and NCR1 mAb blocking and 
heparin inhibition experiments reduce the enhanced 
NK cell cytolytic activity to BPTF KD targets in vitro. 
Also consistent, we observe rescue of BPTF KD tumor 
growth when NCR1 blocking mAb are used in vivo and 
is consistent with other reports that NCR1 is important 
for antitumor activity [5, 43, 44]. Coincident with reduced 
cell surface heparanase, Western blotting identified HSPGs 
which increase in abundance on the surface of BPTF KD 
cells. Heparanase binds HSPGs, stimulating endocytosis 
and eventually HS cleavage, which could explain the 
observed increased cell surface HSPG levels on BPTF KD 
cells [41]. These results in total suggest a model where 
BPTF upregulates heparanase expression to down regulate 
cell surface HSPG levels, a co-ligand to NCR1, reducing 
NK cell cytolytic activity. While this model is consistent 
with the data we cannot rule out that bonified, and yet 
unidentified, NCR ligands are NURF regulated which 
contribute to changes in NK cell activity [45].
The significance of BPTF, and by extension 
NURF, regulation of HPSE in cancer could have broader 
implications. HPSE is commonly upregulated in cancer 
cells to impact angiogenesis, metastasis, tumor growth 
and inflammation [11]. It is therefore plausible that 
differences in tumor shape with BPTF KD could result 
from abnormal angiogenesis, or establishing a fibrin shell. 
Decreases in heparanase levels could also contribute to 
defects in metastases, as previously observed with BPTF 
KD melanoma tumors [46]. Defects could result from 
reductions in cell motility [45], or from enhancements of 
NK cell antitumor activity which is most significant to 
metastatic cancer cells [47]. These hypotheses, partially 
supported by our data, warrant more detailed studies on 
roles for BPTF during metastasis.
NK cells have greatest therapeutic significance to 
hematological malignancies, where NK cell activity can 
result in disease remission. NK cell activity against solid 
tumors is less significant because the immune suppressive 
TME inhibits NK cell infiltration and activity [48]. We 
show for the first time that depleting BPTF in the TME 
could circumvent problems inherent to the use of NK 
cells as an immunotherapy toward solid tumors. BPTF 
depletion in 66cl4 tumors with rAd resulted in tumor 
regression with about 18% frequency, despite incomplete 
BPTF KD. Regression could result from the elevated 
IFNγ converting the TME to a Th1 microenvironment 
and enhancing the activity of other effector cells, or from 
promoting epitope spreading, which could expand novel 
tumor reactive T cell clones [49]. We speculate that tumor 
regression is not observed in the 4T1 model because of 
significant immunosuppressive activity of the remaining 
myeloid derived suppressor cells after gemcitabine 
treatments [50]. It is also noted that there are observed 
differences in the immune response between mouse and 
human BPTF KD vs BPTF low tumors. Using the mouse 
tumor models we do not detect significant differences 
in NK cell abundance with BPTF KD, but differences 
in abundance are observed in human breast tumors with 
low BPTF expression. These differences could be due to 
differences in how mouse tumors or NK cells respond 
to low intratumor BPTF levels compared to similar 
conditions in humans. Alternatively, increased infiltration 
of NK cells in BPTF low human breast tumors could result 
from increased CD8 T cell antitumor activity, which we 
previously observed to the 4T1 mouse breast tumor model 
[19]. To resolve these unknowns, expanded studies on the 
response of human tumors to BPTF inhibition will need 
to be conducted, which was limited in the current study to 
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the use of cancer cell lines in vitro. It is our ultimate goal 
to translate these findings into a novel immunotherapy, 
which could be initiated by using newly identified BPTF 
bromodomain small molecule inhibitors [51] alone or 
in combination with established immune stimulating 
chemotherapies [52] or immunotherapies like NK cell 
adoptive cell transfer [53].
MATERIALS AND METHODS
Mice
BALB/cJ, NOD/SCID/Ifrg2r-/- (NSG) and C57BL/6-
Tg(TcraTcrb)1100Mjb/J (OT1) female mice 6-8 weeks of 
age weighting ~ 20 g (Jackson Laboratory) were housed 
under aseptic barrier conditions as approved by Virginia 
Commonwealth University IACUC.
Cell culture
67NR, 66cl4, 4T1 (Wayne State University, 2010) 
SY5Y and HEK 293T (ATCC, 2010) were cultured in 
complete media (CM) (DMEM, 10% FBS, 1% NEAA, 
1% glutamine, and 1% penicillin/streptomycin). T47D 
and MDA-MB-436 (ATCC, 2010) were cultured in 
RPMI, 10% FBS, 1% NEAA, 1% glutamine, 1% 
penicillin/streptomycin and 5 μg/ml insulin. NK-92 
cells (ATCC, 2012) were cultured in Alpha MEM, 
12.5% horse serum, 12.5% FBS, 2 mM L-glutamine, 
1.5 g/L sodium bicarbonate, 0.2 mM inositol, 0.1 mM 
2-mercaptoethanol, 0.02 mM folic acid and 200 U/ml Il-2. 
OT1 T cells were cultured in CM with 1% HEPES, 5x10-
5 M 2-mercaptoethanol and 500 U/ml mouse Il-2. Cell 
lines were validated by Wayne State University or ATCC 
prior to shipment by short tandem repeat (STR) profiling. 
Mycoplasma contamination was tested and confirmed to 
be negative every 2 years using Universal Mycoplasma 
Detection Kit (ATCC).
ShRNAs were introduced into 67NR and 66cl4 cells 
using the pSIREN-RetroQ system (Clonetech). pSIREN 
plasmids Ctrl-sh1, Ctrl-sh2, Bptf-sh1, Bptf-sh2, HPSE-
sh1, HPSE-sh2 are available at Addgene as stock numbers 
73665, 73666, 73667, 83045, 92033, 92034 respectively. 
ShRNAs were introduced into T47D, MDA-MB-436 and 
SH-SY5Y cells using the lentiviral pLVTHM system. 
pLVTHM plasmids Ctrl-sh1, Bptf-sh1, Bptf-sh2 are 
available at Addgene as stock numbers 83046, 83277, 
83278, respectively. Transduced cells were selected with 
0.5 μg/ml puromycin after 48 hours.
Replication-deficient adenovirus
To construct rAd-BPTF and rAd-Luc, we used the 
AdenoQuick cloning system (OD260, Inc.) according to 
the manufacturer’s instructions. pAD388 cosmids Ctrl-sh, 
Bptf-sh are available at Addgene as stock numbers 83275, 
83276, respectively. The cosmid DNA was transfected 
into HEK-293T cells and serially amplified 3 times to 
obtain high titer virus [54]. Virus titer was determined 
by TCID50 according to the manufacturer’s instructions. 
66cl4 and 4T1 cells were infected with 1x106 PFU rAd 
twice during a one week period.
Spleens from OT1 mice were harvested and depleted 
of erythrocytes with RBC lysis buffer and cocultured with 
mitomycin C-treated B16F10-OVA cells for 3 weeks. 
3x106 cultured NK-92 or 5x105 expanded OT1 T cells 
were then infected with 2x107 or 2x106 rAd in a volume of 
10 ml or 1 ml for 5 days.
Tumor studies
1x105 67NR cells and 1x104 66cl4 cells were 
injected into the fourth mammary fat pad of BALB/c or 
NSG mice. Tumors were analyzed at 21 days (67NR) 
or 28 days (66cl4). For rAd studies, BALB/c mice were 
inoculated with 1x106 66cl4 or 3x1054T1 cells and injected 
intratumorally with rAd-Luc or rAd-BPTF (1x109 PFU in 
100ul) every 3 days for 3 weeks once tumors were ~5 mm 
in any dimension. Animals were euthanized 1 week after 
the last rAd injection. For 4T1 studies, mice were injected 
intraperitoneally (I.P.) with 1.2 mg/mouse gemcitabine 
5 days after tumor inoculation and once every 7 days 
thereafter.
mAb depletions
GK1.5, 2.43 and SH-34 mAb depletions were 
performed as described previously [19]. Briefly, mAbs 
were purified from ascites fluid by ammonium sulfate 
fractionation and 225 μg/mouse was injected on day 
-2, and -1. Tumors were inoculated on day 0 and 
mAb was injected once every 5 days following tumor 
inoculation.
mNCR1.15 blockade
100 μg/mouse mNCR1.15 (Center for Proteomics, 
University of Rijeka, Croatia) was injected on day -2 and 
-1. Cell lines were inoculated on day 0 and mNCR1.15 
was injected once every 5 days thereafter.
Western blot
For total extracts, protein from cell cultures or 
homogenized tumors was extracted by TRI Reagent. Cell 
surface protein extraction was performed as described 
previously [55]. Primary antibodies: anti-BPTF (Millipore 
Cat# ABE024), anti-HS (Millipore Cat# MAB2040), and 
anti-HPSE (Santa Cruz Cat# sc25826) then anti-mouse 
or rabbit HRP secondary (Cell Signaling). Loading was 
determined Cyclophilin B.
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NK cell cytotoxicity assay
NK cells were purified from the spleen of naïve 
BALB/c mice by negative selection using MACS 
separation (Miltenyi Biotech). Purified mouse NK cells 
or cultured NK-92 cells were placed on mitomycin 
C-treated targets for 24 hrs (mouse NK cells with mouse 
targets), 7 hrs (NK-92 cells with mouse targets) or 4 hrs 
(NK-92 cells on human targets). For antibody blocking 
experiments, NK cells were pre-incubated for 1 hr with 
10 μg/ml blocking antibodies to NCR1 (mNCR1.15 from 
Stipan Jonjic, Center for Proteomics, University of Rijeka, 
Croatia), hNKp46 (Biolegend Cat# 13614), hNKp30 
(Biolegend Cat# 325204) or hNKG2D (BD Pharmingen 
Cat# 552866). For hyperactivation, cocultured mouse NK 
cells were treated with 0.8 μM PMA, 0.35 μM Ionomycin 
and 50 U/ml IL-2. For media preconditioning, mitomycin 
C treated targets were incubated for 24 hrs, growth media 
was then removed and incubated with NK cells for 24 
hrs before assay on targets. For heparin competition 
experiments, cocultures were incubated with 100 μg/
ml heparin (Sigma) in growth media during coculture 
with target cells. For heparinase treatment, 66cl4 cells 
were pretreated with 1 U/ml bacterial heparinase I/III 
(Sigma) in DMEM, 1% BSA for one hr at 37°C before 
coculture with NK cells. Cell death was measured using 
the CytoTox 96® Non-Radioactive Cytotoxicity Assay 
(Promega).
qRT-PCR
Quantitative RT-PCR was performed as described 
previously [19]. Primer pairs are found in Supplementary 
Data Set 2.
Flow cytometry
Cultured 67NR and 66cl4 cells were stained with 
H2-Kd (Cat# 553566), H2-Dd (Cat# 558917), H2-Ad 
(Cat# 553548), Qa1 (Cat# 559829) antibodies or Annexin 
V (Cat# 556421), and 7AAD viability dye. To measure 
NK activity, mouse NK cells were incubated for 24 hours 
with mitomycin C treated targets, removed and stained 
with NCR1 (Cat# 137605) (Biolegend) and CD69 (Cat# 
561932) antibodies and 7AAD viability dye. To measure 
NK cells in the spleen, splenocytes were stained with CD3 
and DX5 (Cat#561066) antibodies and 7AAD viability dye.
Tumor infiltrating lymphocytes were purified as 
described previously [19]. Purified lymphocytes were 
stained with NCR1, CD69, CD3 (Cat# 553060), or 
CD8 (Cat# 100706) antibodies and 7AAD viability dye. 
All antibodies used for flow cytometry are from BD 
Pharmingen, unless otherwise specified.
The NCR1-Ig fusion protein (gift from Ofer 
Mandelboim from The Hebrew University of Jerusalem) 
was purified from HEK293T cells as described previously 
[56]. For heparinase treatment, 67NR and 66cl4 cells were 
treated with 10 U/ml bacterial heparinase I/III (Sigma) in 
1% BSA DMEM for 1 hr at 37°C. Then 1x105 cells were 
incubated with 1 μg NCR1-Ig for 1 hr at 4°C and stained 
with PE- anti-human-IgG Fc (Biolegend Cat# 409304).
Chromatin immunoprecipitation (ChIP)
ChIP was performed as previously described [15]. 
Primer pairs are found in Supplementary Data Set 2.
Enzyme linked immunosorbent assay (ELISA)
Tumors were minced and suspended in hanks 
balanced salts supplemented with complete protease 
inhibitor. After 3 cycles of freeze thaw, samples were 
centrifuged at 15,000 x rcf at 4°C for 15 min and the 
supernatant was collected. ELISA for IFNγ (R&D 
Systems) was performed according to the manufacturer’s 
instructions.
NCR1 reporter assay
NCR1-ζ, Il-2 reporter BW cells (gift from Ofer 
Mandelboim from The Hebrew University of Jerusalem) 
were cocultured with 67NR or 66cl4 targets at 1:1 E:T 
ratio for 48 hrs. Il2 expression was measured by qRT-PCR 
and normalized to NCR1-ζ expression. Primer pairs are 
found in Supplementary Data Set 2.
Microarray
RNA extraction, microarray analysis and statistical 
analysis were performed as described [57, 58]. Data is 
available as GEO accession #GSE785756.
Bioinformatics
RNAseq Zscores were downloaded from The 
Cancer Genome Atlas (TCGA). For each cancer, patients 
were divided into high (n = 325) and low (n = 169) 
BPTF expressing groups using a Zscore cutoff of >1 
and <-1 respectively. A t-test was performed to evaluate 
differential expression of HPSE between the BPTF 
high and BPTF low groups. For immune cell markers, 
an unpaired t-test was performed to assess differential 
expression of immune cell markers between BPTF low 
and BPTF high samples.
Microarray expression profiles from patients 
with breast cancer were downloaded from NCBI GEO 
(GSE2109) (n = 348). Patients expressing 1 standard 
deviation above or below the mean level of expression 
were binned as BPTF high (n = 40) and BPTF low (n 
= 45), respectively. Probe level data from both groups 
were used as input for the CIBERSORT deconvolution 
algorithm. Immune profiles from BPTF high and BPTF 
low groups were compared.
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Statistics
Excel was used to calculate statistical differences 
between groups using the two-tailed Student’s t-test.
Abbreviations
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factor; ChIP, chromatin immunoprecipitation; GO, 
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antibody; NCR, natural cytotoxicity receptor; NK, natural 
killer; NURF, nucleosome remodeling factor; P+I, PMA + 
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tumor microenvironment.
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